OQS
TVTX icon

Occudo Quantitative Strategies’s Travere Therapeutics TVTX Stock Holding History

Occudo Quantitative Strategies’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-36,821
Closed -$907K – 1384
2022
Q3 		$907K Sell
36,821
-27,153
-42% -$702K 0.07% 438
2022
Q2 		$1.55M Buy
63,974
+38,369
+150% +$965K 0.13% 248
2022
Q1 		$660K Buy
+25,605
New +$680K 0.06% 536

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Occudo Quantitative Strategies's TVTX Position: Q4 2022 in Review

Occudo Quantitative Strategies sold out of Travere Therapeutics (TVTX) in Q4 2022, closing a stake of 36,821 shares — an estimated $907K sold.

Occudo Quantitative Strategies first reported a position in TVTX in Q1 2022 and held it in 3 quarters. The position peaked at $1.55M in Q2 2022. 155 funds tracked by Wall St. Rank hold TVTX as of Q4 2022.

  • Occudo Quantitative Strategies reported no remaining Travere Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 36,821 Travere Therapeutics shares in Q4 2022, an estimated $907K.
  • Occudo Quantitative Strategies first reported a position in Travere Therapeutics in Q1 2022 and held it in 3 quarters.
  • Occudo Quantitative Strategies's Travere Therapeutics position peaked at $1.55M in Q2 2022.
  • 155 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.